These findings indicate that the anti-tumor efficacy of BRU+PD is achieved by inhibiting the expression of Nrf2 as well as its downstream target genes, thereby increasing ROS levels leading to inhibiting tumor cell proliferation. This evidence concerns the gene NFE2L2 and neoplasm.